Cargando…
P10 Ceftazidime/avibactam for OXA-48 urinary tract infections—a 12 month remissive study
BACKGROUND: Ceftazidime/avibactam is a novel antibiotic for MDR bacterial infections. Despite its high cost, from 1 January 2022 to 31 December 2022, 23 patients out of 230 hospital beds at the Hospital of Cascais received it. Seven of these patients had OXA-48-producing urinary tract infections (UT...
Autores principales: | Fernandes, Afonso Paes, Silva, Beatriz, Coutinho, Ana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395424/ http://dx.doi.org/10.1093/jacamr/dlad077.014 |
Ejemplares similares
-
OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs
por: Fröhlich, Christopher, et al.
Publicado: (2019) -
Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates
por: Castanheira, Mariana, et al.
Publicado: (2021) -
Nosocomial meningitis caused by ESBL- and OXA-48-producing Klebsiella pneumoniae and treated with ceftazidime-avibactam. Report of one case and review of the literature
por: De Santis, Lucía B Valiente, et al.
Publicado: (2022) -
Evaluation of ceftazidime/avibactam for treatment of carbapenemase-producing carbapenem-resistant Enterobacterales with OXA-48 and/or NDM genes with or without combination therapy
por: Alqahtani, Hajar, et al.
Publicado: (2022) -
Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021)